Eli Lilly’s Mounjaro Loses Ground to Less-Expensive Semaglutide Generics & Innovator Novo Nordisk’s Products

Why It Matters

The price erosion threatens Mounjaro’s market dominance and signals a shift toward affordable GLP‑1 therapies in emerging markets, reshaping revenue streams for global pharma players.

Key Takeaways

• Mounjaro sales dropped 15% month‑over‑month.
• Generic semaglutide prices cut 50‑80% versus brand.
• 13 firms released 26 semaglutide variants in India.
• Novo Nordisk still leads semaglutide with ₹45 crore.
• GLP‑1 segment revenue fell ₹11 crore in March.

Pulse Analysis

The rapid rollout of generic semaglutide in India marks a watershed moment for the GLP‑1 market. Patent expirations in March unlocked a flood of domestic formulations, ranging from injectable vials to oral tablets, allowing manufacturers to undercut Novo Nordisk and Eli Lilly by up to 80 percent. This price compression is already reflected in sales data: while Mounjaro’s revenue slipped to ₹114 crore, generic semaglutide climbed to ₹59 crore, illustrating how cost‑sensitive patients and prescribers are gravitating toward cheaper alternatives.

For Eli Lilly, the erosion of Mounjaro’s momentum underscores the vulnerability of premium‑priced GLP‑1 agents in price‑sensitive markets. The company’s reliance on tirzepatide’s efficacy narrative may no longer suffice when competitors can offer comparable outcomes at a fraction of the cost. Meanwhile, Novo Nordisk’s strategy of pairing price parity with strategic partnerships—such as with Emcure and Abbott—helps preserve its market share, but the firm must brace for further dilution as more generics gain regulatory approval and distribution reach.

Looking ahead, the Indian GLP‑1 landscape is poised for an "exponential growth" phase, driven by aggressive launches and expanding patient access. Regulators are likely to tighten oversight to curb off‑label use, yet the fundamental demand for obesity and diabetes treatments will sustain volume growth. Global pharma players must adapt, either by introducing cost‑effective biosimilars, pursuing localized manufacturing, or leveraging differentiated delivery technologies to maintain relevance in an increasingly competitive arena.